-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15

Benzinga·03/31/2026 14:23:46
Listen to the news
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $9 to $15.